XOMA to Present At Lazard Capital Markets Healthcare Conference On
MSN MoneyCentral - XOMA has royalty interests in RAPTIVA(r) (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Merck Serono S.A.) to treat moderate-to-severe plaque psoriasis, and LUCENTIS(r) (ranibizumab injection), a monoclonal
Friday, November 23, 2007
XOMA to Present At Lazard Capital Markets Healthcare Conference On
Bookmark this post:
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment